ngµç×ÓÓÎÏ·ÐÂÎÅÍøѶ£¨Í¨Ñ¶Ô±Ò¶»Ûݼ¡¢¡¢¹Ø¼ÒÆæ¡¢¡¢ÌÆÑÞÀö£©ÈÕÇ°£¬£¬£¬ngµç×ÓÓÎÏ·ÖÐɽÑÛ¿ÆÖÐÐÄÔÚÖ齭гÇÔºÇøʵÑéÂ¥ÕÙ¿ªÃ½ÌåÐû²¼»á£¬£¬£¬½éÉÜÆä×îеÄÑо¿Ð§¹û¡ª¡ªngµç×ÓÓÎÏ·ÖÐɽÑÛ¿ÆÖÐÐÄÑʤ½ÌÊÚÍŶӺ͸´µ©´óѧÁ¥ÊôÑÛ¶ú±Çºí¿ÆҽԺǮ½­½ÌÊÚÍŶÓÔÚ¹ú¼Ê¶¥¼¶Ò½Ñ§ÆÚ¿¯ÃÀ¹úҽѧ»áÔÓÖ¾£¨JAMA£©½ÒÏþÔ­´´ÁÙ´²Ñо¿ÂÛÎÄ£¬£¬£¬Ö¤ÊµÁË¡°3¸öÁƳ̵ÄCEV»¯ÁÆ·½°¸Óë¹Å°å6ÁƳ̷½°¸¹ØÓÚ¸ßΣÊÓÍøĤĸϸ°ûÁö¾ßÓÐÏàͬµÄÁÆЧ¡±¡£¡£¡£¡£¡£Ðû²¼»áÓÉngµç×ÓÓÎÏ·ÖÐɽÑÛ¿ÆÖÐÐÄÖ÷ÈΡ¢¡¢Ò½ÔºÔº³¤¡¢¡¢ÑÛ²¡·ÀÖÎÌìÏÂÖصãʵÑéÊÒÖ÷ÈÎÁÖºÆÌí½ÌÊÚÖ÷³Ö£¬£¬£¬ÏîÄ¿ÈÏÕæÈË¡¢¡¢ÂÛÎÄ×îºóͨѶ×÷ÕßÑʤ½ÌÊÚ½éÉܸÃÑо¿Ð§¹û¡£¡£¡£¡£¡£

Ñо¿ÍŶÓ

ÊÓÍøĤĸϸ°ûÁöÊǶùͯÑÛÄÚ×î³£¼ûµÄ¶ñÐÔÖ×Áö£¬£¬£¬È«ÌìÏÂÿÄêÔ¼ÓÐ8000ÀýÐÂÔö»¼¶ù¡£¡£¡£¡£¡£¾ßÓв¡Àí¸ßΣÒòËصÄÍíÆÚÊÓÍøĤĸϸ°ûÁö»¼¶ùÓнϸߵÄ­ÄÚÒÔ¼°Ô¶´¦×ªÒÆ·çÏÕ£¬£¬£¬ÕâЩתÒƳ£µ¼Ö²¡ÇéѸËÙ¶ñ»¯£¬£¬£¬ÑÏÖØÍþв»¼¶ùÉúÃü¡£¡£¡£¡£¡£ÏÖÔÚ¹ØÓÚÕâÀ໼¶ùÖ÷ÒªµÄÖÎÁÆ·½°¸ÎªÊõºó¸¨Öú»¯ÁÆ¡£¡£¡£¡£¡£µ«ÓÉÓÚȱ·¦Õë¶Ô¾ßÓв¡Àí¸ßΣÒòËصÄÍíÆÚÊÓÍøĤĸϸ°ûÁö»¼¶ùµÄÁÙ´²Ëæ»úÊÔÑéÊý¾Ý£¬£¬£¬ÏÖÔÚÉÐÎÞ·¨È·¶¨×î¼ÑµÄ»¯ÁÆÁƳÌ¡£¡£¡£¡£¡£

¹Å°åµÄ6¸öÁƳÌCEV£¨¿¨²¬¡¢¡¢ÒÀÍв´Üպͳ¤´ºÐ¼·½°¸ËäÈ»ÓÐÓ㬣¬£¬µ«ÁƳ̹ý³¤¡¢¡¢²»Á¼·´Ó³¼°²¢·¢Ö¢½Ï¶à£¬£¬£¬¸ø»¼¶ùºÍÆä¼ÒÍ¥´øÀ´¼«Öصļ縺¡£¡£¡£¡£¡£ÎªÁËËõ¶ÌÁƳ̣¬£¬£¬ïÔÌ­»¯ÁƸ±×÷Ó㬣¬£¬¼õÇỼ¶ùºÍ¼ÒÍ¥µÄ¼ç¸º£¬£¬£¬Ñʤ½ÌÊÚÍŶӿª´´ÐÔµØÌá³öÁË3¸öÁƳÌCEV»¯ÁÆ·½°¸£¬£¬£¬²¢Ì½Ë÷Á˱¾·½°¸Óë¹Å°å·½°¸ÊÇ·ñ¾ßÓÐÏàͬµÄÓÐÓÃÐÔ¡£¡£¡£¡£¡£

¿ËÈÕ£¬£¬£¬ngµç×ÓÓÎÏ·ÖÐɽÑÛ¿ÆÖÐÐÄÑʤ½ÌÊÚÍŶÓÁªºÏ¸´µ©´óѧÁ¥ÊôÑÛ¶ú±Çºí¿ÆҽԺǮ½­½ÌÊÚÍŶÓÔÚ¹ú¼Ê¶¥¼âҽѧÆÚ¿¯JAMA½ÒÏþÁËÌâΪ¡°Three vs 6 Cycles of Chemotherapy for High-Risk Retinoblastoma £º£ºA Randomized Clinical Trial¡±µÄÑо¿ÂÛÎÄ¡£¡£¡£¡£¡£ÕâÏîÑо¿ÊÇngµç×ÓÓÎÏ·ÖÐɽÑÛ¿ÆÖÐÐÄÔÚJAMAÉϵĵڶþƪԭ´´ÁÙ´²Ñо¿ÂÛÎÄ£¬£¬£¬Ò²ÊÇÎÒ¹úÑÛ¿ÆÁìÓòÔÚ¸ÃÆÚ¿¯½ÒÏþµÄµÚ¶þƪÁÙ´²Ñо¿ÂÛÖø¡£¡£¡£¡£¡£

±¾Ñо¿»Ø¸²Á˸ßΣÊÓÍøĤĸϸ°ûÁö»¼¶ùÊõºó¸¨Öú»¯ÁƵÄ×î¼ÑÁƳÌÎÊÌ⣬£¬£¬Ñо¿Ð§¹ûÅú×¢£¬£¬£¬3¸öÁƳ̵ÄCEV»¯ÁÆ·½°¸Óë¹Å°å·½°¸¾ßÓÐÏàͬµÄÁÆЧ£¬£¬£¬ÕâÓÐÍûʹ¸ü¶à¸ßΣÊÓÍøĤĸϸ°ûÁö»¼¶ùÊÜÒ沢дÈëÖ¸ÄÏ¡£¡£¡£¡£¡£

ÕâÏîÇ°Õ°ÐÔ¡¢¡¢·ÇÁÓЧËæ»ú±ÈÕÕÁÙ´²Ñо¿ÄÉÈëÁË187Àý½ÓÊÜÑÛÇòÕª³ýÊõÇÒ¾ßÓв¡Àí¸ßΣÒòËصĵ¥ÑÛÊÓÍøĤĸϸ°ûÁö»¼¶ù¡£¡£¡£¡£¡£»¼¶ùËæ»ú·ÖΪÁ½×飬£¬£¬»®·Ö½ÓÊÜ3¸öÁƳ̻ò6¸öÁƳ̵ÄCEV»¯ÁÆ¡£¡£¡£¡£¡£Ñо¿µÄÖ÷Ҫϳ¡Ö¸±êΪÎÞ²¡ÉúÑÄÂÊ£¨DFS£©£¬£¬£¬´ÎҪϳ¡Ö¸±êΪ×ÜÉúÑÄÂÊ¡¢¡¢Çå¾²ÐÔ¡¢¡¢¾­¼Ã¸ºµ£¡£¡£¡¢¡¢»¼¶ùÉúÑÄÖÊÁ¿µÈ¡£¡£¡£¡£¡£

Ñо¿Ð§¹ûÏÔʾ£¬£¬£¬ÔÚÖ÷Ҫϳ¡Ö¸±ê£¨5ÄêÎÞ²¡ÉúÑÄÂÊ£©·½Ã棬£¬£¬3ÁƳÌ×éºÍ6ÁƳÌ×é»®·ÖΪ90.4%ºÍ89.2%£¬£¬£¬ÎÞÏÔÖø²î±ð¡£¡£¡£¡£¡£±ðµÄ£¬£¬£¬ÔÚ5Äê×ÜÉúÑÄÂÊ·½Ã棬£¬£¬Á½×éÒ²ÎÞͳ¼Æѧ²î±ð£¨91.5% VS 89.3%£©¡£¡£¡£¡£¡£

3ÁƳÌ×é±ÈÕչŰå6ÁƳÌ×飬£¬£¬ÎÞ²¡ÉúÑÄÂÊÎÞÏÔÖø²î±ð

ÔÚÖÎÁÆÇå¾²ÐÔ·½Ã棬£¬£¬3ÁƳÌ×éÓÐ79Ãû£¨80.6%£©»¼¶ùÂÄÀúÁ˹²282´Î²»Á¼ÊÂÎñ¡£¡£¡£¡£¡£¶øÔÚ6ÁƳÌ×éÖУ¬£¬£¬89Ãû»¼¶ù£¨95.7%£©ÂÄÀúÁË×ܼÆ681´Î²»Á¼ÊÂÎñ¡£¡£¡£¡£¡£±ðµÄ£¬£¬£¬ÔÚ¾­¼Ã¼ç¸º·½Ã棬£¬£¬3ÁƳÌ×é±È6ÁƳÌ×éÖ±½Ó±¾Ç®ºÍ¼ä½Ó±¾Ç®¸üµÍ¡£¡£¡£¡£¡£

±¾Ñо¿Ö¤Êµ£¬£¬£¬3¸öÁƳÌCEV»¯ÁÆÔÚÔ¤·ÀתÒƺͽµµÍéæÃüÂÊ·½ÃæÓë6¸öÁƳÌͬÑùÓÐÓ㬣¬£¬ÇÒ¸±×÷ÓøüÉÙ£¬£¬£¬±¾Ç®¸üµÍ¡£¡£¡£¡£¡£

Õâ¿ÉÄܳÉΪ¡°¾ßÓиßΣ²¡ÀíÌØÕ÷µÄÊÓÍøĤĸϸ°ûÁö¡±µÄÖÎÁÆбê×¼£¬£¬£¬ÓÐÍûʹ¸ü¶à»¼¶ùÊÜÒ棬£¬£¬²¢¿ÉÄܱ»Ð´Èë¹ú¼ÊÖ¸ÄÏ¡£¡£¡£¡£¡£

JAMAÆÚ¿¯¶Ô±¾Ñо¿¸øÓèÁ˸߶ÈÆÀ¼Û£¬£¬£¬ÒÔΪÕâÏîÑо¿¶ÔÓÐÊýÖ×ÁöÖÎÁƾßÓÐÖØ´óÒâÒå¡£¡£¡£¡£¡£¹ú¼Ê¶¥¼¶ÑÛÖ×Áöר¼ÒCarol Lally Shields½ÌÊÚ̸Â۳ƣ¬£¬£¬¸ÃÑо¿µÄ3¸öÁƳÌCEV»¯ÁÆ·½°¸ÊÇÀï³Ì±®Ê½µÄ£¬£¬£¬ÓÉÓÚËü¼ÈÕü¾ÈÁËÉúÃü£¬£¬£¬ÓÖ¼õÇáÁË»¼Õߵľ­¼ÃѹÁ¦£¬£¬£¬Ìá¸ßÁËÖÎÁÆÍê³ÉÂÊ¡£¡£¡£¡£¡£

ngµç×ÓÓÎÏ·ÖÐɽÑÛ¿ÆÖÐÐÄ¡¢¡¢ÑÛ²¡·ÀÖÎÌìÏÂÖصãʵÑéÊÒΪ±¾Ñо¿µÚÒ»×÷Õßµ¥Î»ºÍ×îºóͨѶ×÷Õßµ¥Î»¡£¡£¡£¡£¡£ÖÐɽÑÛ¿ÆÖÐÐÄÑʤ½ÌÊں͸´µ©´óѧÁ¥ÊôÑÛ¶ú±Çºí¿ÆҽԺǮ½­½ÌÊÚΪÅäºÏͨѶ×÷Õߣ¬£¬£¬ÖÐɽÑÛ¿ÆÖÐÐĸ±Ö÷ÈÎҽʦҶ»Ûݼ¡¢¡¢¸´µ©´óѧÁ¥ÊôÑÛ¶ú±Çºí¿ÆÒ½Ôº¸±Ö÷ÈÎҽʦѦ¿µÎªÅäºÏµÚÒ»×÷Õß¡£¡£¡£¡£¡£

ÂÛÎÄÁ´½Ó£º£º

https://jamanetwork.com/journals/jama/article-abstract/2825162